Plain-English translation of NCT06733935 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called , which is a type of cell therapy that uses natural killer cells engineered to fight autoimmune diseases. Researchers want to see if can safely and effectively treat four serious autoimmune conditions: systemic sclerosis, inflammatory muscle disease, vasculitis, and rheumatoid arthritis. The trial will test different doses and carefully monitor how well the treatment works and what side effects occur.
Current treatments for these autoimmune diseases don't work well enough for all patients, and some people can't tolerate them. This medication is designed to work differently by using your own immune cells in a new way to help control the disease.
You likely qualify if…
You likely don't qualify if…
You will first receive two chemotherapy drugs ( and ) to prepare your body for the new cells, though doctors may adjust this if you have certain blood count issues. Then you will receive three doses of . You will have multiple clinic visits to have blood tests, imaging, and physical exams to check how you respond to the treatment and watch for any side effects. The study will track your health and disease activity over time to see if this medication helps improve your symptoms.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States